{"id":5738,"date":"2006-02-09T07:17:39","date_gmt":"2006-02-09T06:17:39","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=5738"},"modified":"2013-12-07T08:37:11","modified_gmt":"2013-12-07T08:37:11","slug":"ranbaxy-launches-two-new-arvs-in-india","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/5738","title":{"rendered":"Ranbaxy launches two new ARVs in India"},"content":{"rendered":"<p><strong>Ranbaxy Laboratories Limited (RLL) announced that the Company is introducing two new anti-HIV products, Virolis-E and Virocomb-E, in India.<\/strong><\/p>\n<p>Both products contain three Anti Retroviral drugs each and offer WHO recommended first line Highly Active Anti Retroviral Therapy (HAART) in daily use packs.<\/p>\n<p>Virolis-E is a compliance pack containing two fixed dose combination tablets of 3TC 150mg &amp; d4T 30\/40mg and one tablet of efavirenz 600mg.<\/p>\n<p>Virocomb-E is also a compliance pack and contains two fixed dose combination tablets of 3TC 150mg &amp; AZT 300mg and one tablet of efavirenz 600mg.<\/p>\n<p>Source: Ranbaxy Press Release<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ranbaxy Laboratories Limited (RLL) announced that the Company is introducing two new anti-HIV products, Virolis-E and Virocomb-E, in India. Both products contain three Anti Retroviral drugs each and offer WHO recommended first line Highly Active Anti Retroviral Therapy (HAART) in &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-5738","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=5738"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5738\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=5738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=5738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=5738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}